A5035136737- HIV Research and Treatment
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Long-Term Effects of COVID-19
- SARS-CoV-2 detection and testing
- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- RNA and protein synthesis mechanisms
- COVID-19 and Mental Health
- Diabetes and associated disorders
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- HIV, Drug Use, Sexual Risk
- Biosensors and Analytical Detection
- Adolescent Sexual and Reproductive Health
- Mosquito-borne diseases and control
- Herpesvirus Infections and Treatments
- Viral gastroenteritis research and epidemiology
- Protein purification and stability
- Animal Virus Infections Studies
- CAR-T cell therapy research
- Complement system in diseases
Icahn School of Medicine at Mount Sinai
2020-2024
James J. Peters VA Medical Center
2020-2024
Université de Strasbourg
2017-2022
Inserm
2017-2022
Mount Sinai Health System
2022
Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine
2018
Children's Hospital
1995
The global coronavirus disease 2019 (COVID-19) pandemic has mobilized efforts to develop vaccines and antibody-based therapeutics, including convalescent-phase plasma therapy, that inhibit viral entry by inducing or transferring neutralizing antibodies (nAbs) against the severe acute respiratory syndrome 2 (SARS-CoV-2) spike glycoprotein (CoV2-S). However, rigorous efficacy testing requires extensive screening with live virus under onerous biosafety level 3 (BSL3) conditions, which limits...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people globally. Virus infection requires the receptor-binding domain (RBD) spike protein. Although studies have demonstrated anti-spike and -RBD antibodies to be protective in animal models, convalescent plasma as a promising therapeutic option, little is known about immunoglobulin isotypes capable blocking infection.We studied spike- RBD-specific plasma/serum samples using multiplex bead assay. We also...
Abstract SARS-CoV-2 has infected millions of people and is on a trajectory to kill more than one million globally. Virus entry depends the receptor-binding domain (RBD) spike protein. Although previous studies demonstrated anti-spike –RBD antibodies as essential for protection convalescent plasma promising therapeutic option, little known about immunoglobulin (Ig) isotypes capable blocking virus entry. Here, we studied spike- RBD-specific Ig in plasma/sera from two acutely 29 individuals....
The development of an effective vaccine against HIV-1 has proven to be challenging. Broadly neutralizing antibodies (bNAbs), whilst exhibiting neutralization breadth and potency, are elicited only in a small subset infected individuals have yet induced by vaccination. Case-control studies RV144 identified inverse correlation infection risk with (Abs) the V1V2 region gp120 high antibody-dependent cellular cytotoxicity (ADCC) activity. activity Abs was not found contribute this protective...
Antibodies (Abs) are essential for the host immune response against SARS-CoV-2, and all vaccines developed so far have been designed to induce Abs targeting SARS-CoV-2 spike. Many studies examined Ab responses in blood from vaccinated infected individuals. However, since is a respiratory virus, it also critical understand mucosal at sites of initial virus exposure. Here, we plasma versus saliva convalescent patients. Although levels were significantly lower, strong correlation was observed...
The global COVID-19 pandemic has mobilized efforts to develop vaccines and antibody-based therapeutics, including convalescent plasma therapy, that inhibit viral entry by inducing or transferring neutralizing antibodies (nAbs) against the SARS-CoV-2 spike glycoprotein (CoV2-S). However, rigorous efficacy testing requires extensive screening with live virus under onerous BSL3 conditions which limits high throughput of patient vaccine sera. Myriad BSL-2 compatible surrogate neutralization...
Abstract More than 24 million infections with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were confirmed globally by September 2020. While polymerase chain reaction–based assays are used for diagnosis, there is a need high-throughput, rapid serologic methods. A Luminex binding assay was developed and to assess simultaneously presence of disease 2019 (COVID-19)–specific antibodies in human serum plasma. Clear differentiation achieved between specimens from infected...
HIV-specific broadly neutralizing antibodies (bnAbs) have been isolated from patients with high viremia but also HIV controllers that repress HIV-1 replication. In these elite (ECs), multiple parameters contribute to viral suppression, including genetic factors and immune responses. Defining the correlates associated generation of bnAbs may help in designing efficient immunotherapies. this study, ECs either positive or negative for HLA-B*57 protective allele, treated HIV-infected...
ABSTRACT Follicular helper T cells (Tfh) play an essential role in the affinity maturation of antibody response by providing help to B cells. To determine whether this CD4 + cell subset may contribute spontaneous control HIV infection, we analyzed phenotype and function circulating Tfh (cTfh) patients from ANRS CO21 CODEX cohort who naturally controlled HIV-1 replication undetectable levels compared them treated with similarly low viral loads. HIV-specific cTfh (Tet ), detected Gag-major...
Antibodies are principal immune components elicited by vaccines to induce protection from microbial pathogens. In the Thai RV144 HIV-1 vaccine trial, efficacy was 31% and sole primary correlate of reduced risk shown be vigorous antibody response targeting V1V2 region envelope. against V3 also were inversely correlated with infection in subsets vaccinees. recognizing these regions, however, do not exhibit potent neutralizing activity. Therefore, we examined antiviral potential poorly...
Introduction Antibodies against the SARS-CoV-2 spike protein are a critical immune determinant for protection virus. While virus neutralization is key function of spike-specific antibodies, antibodies also mediate Fc-dependent activities that can play role in or pathogenesis. Methods This study characterized serum antibody responses elicited after two doses heterologous adenovirus-vectored (Ad26/ Ad5) vaccines. Results Vaccine-induced binding titers and Fc-mediated functions decreased over...
SUMMARY Background More than one million infections with the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) have been confirmed. While PCR-based assays are used for diagnosis, high through-put serologic methods needed to detect antibodies seroserveillance and identification of seroconversion, potential plasma donors, nature immune response this pathogen. Methods A Luminex binding assay was assess presence in human sera from COVID-19-infected -uninfected individuals specific...
Abstract Antibodies (Abs) are essential for the host immune response against SARS-CoV-2, and all vaccines developed so far have been designed to induce Abs targeting SARS-CoV-2 spike. Many studies examined Ab responses in blood from vaccinated infected individuals. However, since is a respiratory virus, it also critical understand mucosal at sites of initial virus exposure. Here, we plasma versus saliva convalescent patients. Although levels were significantly lower, strong correlation was...
A fraction of patients with COVID-19 develops severe disease requiring hospitalization, while the majority, including high-risk individuals, experience mild symptoms. Severe has been associated higher levels antibodies and inflammatory cytokines but often among diverse demographics comorbidity status. This study evaluated hospitalized vs. ambulatory demographic risk factors for COVID-19: median age 63, >80% male, >85% black and/or Hispanic. Sera were collected four to 243 days after symptom...
Spontaneous control of HIV replication without treatment in HIV-1 controllers (HICs) was associated with the development an efficient T-cell response. In addition, increasing data suggest that humoral response participates viral clearance.In-depth characterization Ab HICs may help to define new parameters this control.We assessed levels total and HIV-specific IgA IgG subtypes induction their functional potencies - is, neutralization, phagocytosis, antibody-dependent cellular cytotoxicity...
In the semen, both free virus and infected cells are able to establish HIV infection during sexual intercourse. An efficient vaccine should therefore inhibit infectious states. The aim of this study was analyze capacity broadly neutralizing antibodies (bNAbs) transmission by cells.We developed an in-vitro model aiming mimic mucosal via cells. PHA-activated CD4+ T stained with PKH26 from donor A were co-cultured dendritic B in presence bNAbs.We showed that preferential target at early time...
Introduction Neutralizing antibodies (Abs) are one of the immune components required to protect against viral infections. However, developing vaccines capable eliciting neutralizing Abs effective a broad array HIV-1 isolates has been an arduous challenge. Objective This study sought test aimed induce epitopes at V1V2 apex envelope (Env). Methods Four groups rabbits received DNA vaccine expressing domain CRF01_AE A244 strain on trimeric 2J9C scaffold (V1V2-2J9C) along with protein consisting...
Abstract Antibodies are principal immune components elicited by vaccines to induce protection from microbial pathogens. In the Thai RV144 HIV-1 vaccine trial, efficacy was 31% and sole primary correlate of reduced risk shown be vigorous antibody response targeting V1V2 region envelope. against V3 also were inversely correlated with infection in subsets vaccinees. recognizing these regions, however, do not exhibit potent neutralizing activity. Therefore, we examined antiviral potential poorly...
Broadly neutralizing antibodies have been proposed as key actors for HIV vaccine development. However, they display features of highly matured antibodies, hampering their induction by vaccination. As protective broadly should be induced rapidly after vaccination and neutralize the early-transmitted founder (T/F) viruses, we searched whether such may following infection.Sera were collected during acute infection (Day 0) at viral set point (Month 6/12) activity against T/F strains was...
Abstract Since its emergence in 2019, SARS-CoV-2 has infected millions of people and several vaccines have been approved for clinical use worldwide. Antibodies against the spike protein are a critical immune determinant protection this virus. While virus neutralization is key function spike-specific antibodies, antibodies also mediate Fc-dependent activities that can play role or pathogenesis. This study compared Fc properties functions anti-spike elicited by Pfizer/BioNtech Moderna mRNA...